ImmuPharma plc (IMMPF)
For informational purposes only. Not financial advice. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
ImmuPharma plc (IMMPF) with AI Score 44/100 (Weak). ImmuPharma plc is a biopharmaceutical company focused on discovering and developing peptide-based therapeutics for autoimmune, inflammatory, and anti-infective diseases. Market cap: 0, Sector: Healthcare.
Last analyzed: Mar 18, 2026ImmuPharma plc (IMMPF) Healthcare & Pipeline Overview
ImmuPharma plc is a biopharmaceutical company specializing in peptide-based therapeutics, with a focus on autoimmunity and inflammation. Its lead candidate, Lupuzor, targeting lupus, is currently in Phase III trials. The company also develops treatments for fungal infections and antibacterial solutions, operating within the competitive biotechnology sector.
Investment Thesis
ImmuPharma's investment thesis hinges on the successful completion and commercialization of Lupuzor, their lead drug candidate for lupus, currently in Phase III trials. Positive trial results could drive significant value, given the substantial market for lupus treatments. The company's pipeline of peptide-based therapeutics, including BioAMB and BioCin, offers additional potential revenue streams. However, the company faces risks associated with clinical trial outcomes, regulatory approvals, and securing funding for ongoing research and development. With a market capitalization of $0.03 billion and a negative P/E ratio of -6.60, the company's financial performance is closely tied to the success of its clinical programs. Upcoming data releases from the Phase III trial of Lupuzor will be a key catalyst to watch.
Based on FMP financials and quantitative analysis
Key Highlights
- Market capitalization of $0.03 billion reflects the company's current valuation in the biotechnology sector.
- Phase III clinical trial for Lupuzor represents a critical milestone with potential for significant market impact.
- Collaboration with Centre National de la Recherche Scientifique expands the company's research capabilities in diabetes therapeutics.
- Negative P/E ratio of -6.60 indicates that the company is currently not profitable, common for development-stage biopharmaceutical companies.
- Beta of 1.41 suggests that the stock is more volatile than the market average.
Competitors & Peers
Strengths
- Proprietary peptide-based drug development platform.
- Lead product candidate, Lupuzor, in Phase III clinical trials.
- Focus on unmet medical needs in autoimmunity, inflammation, and anti-infectives.
- Collaboration with Centre National de la Recherche Scientifique.
Weaknesses
- Limited financial resources.
- Dependence on the success of Lupuzor.
- Small number of employees.
- OTC market listing.
Catalysts
- Upcoming: Data releases from the Phase III clinical trial of Lupuzor.
- Upcoming: Potential regulatory submissions for Lupuzor.
- Ongoing: Advancement of BioAMB and BioCin through preclinical and clinical development.
- Ongoing: Securing strategic partnerships and licensing agreements.
- Ongoing: Expansion of diabetes therapeutics pipeline through collaboration with Centre National de la Recherche Scientifique.
Risks
- Potential: Failure of Lupuzor Phase III clinical trial.
- Potential: Regulatory rejection of Lupuzor.
- Ongoing: Competition from larger pharmaceutical companies.
- Ongoing: Funding challenges for research and development.
- Ongoing: Risks associated with OTC market listing.
Growth Opportunities
- Successful completion and commercialization of Lupuzor for lupus treatment: The global lupus therapeutics market is projected to reach billions of dollars. Positive Phase III trial results and subsequent regulatory approval could provide ImmuPharma with a significant revenue stream. Timeline: Anticipated data releases and regulatory submissions within the next 12-24 months.
- Development and commercialization of BioAMB for fungal infections: The market for antifungal drugs is substantial, driven by increasing incidence of invasive fungal infections. BioAMB's peptide-based approach could offer advantages over existing treatments. Timeline: Preclinical and clinical development ongoing, with potential for market entry in 3-5 years.
- Advancement of BioCin as a novel antibacterial drug: With rising antibiotic resistance, there is a critical need for new antibacterial agents. BioCin targets high medical need cases and last-line-of-defense situations. Timeline: Preclinical and clinical development ongoing, with potential for market entry in 5-7 years.
- Expansion of diabetes therapeutics pipeline through collaboration with Centre National de la Recherche Scientifique: The diabetes market is large and growing, driven by increasing prevalence of type 1 and type 2 diabetes. Developing novel peptide-based therapies could provide ImmuPharma with a foothold in this market. Timeline: Ongoing research and development, with potential for clinical candidates in 3-5 years.
- Strategic partnerships and licensing agreements: ImmuPharma can leverage partnerships with larger pharmaceutical companies to accelerate the development and commercialization of its pipeline products. Licensing agreements can provide upfront payments and milestone payments, as well as royalties on future sales. Timeline: Ongoing efforts to secure partnerships and licensing agreements.
Opportunities
- Positive results from Lupuzor Phase III trial.
- Expansion of pipeline through research and development.
- Strategic partnerships and licensing agreements.
- Growing market for autoimmune disease treatments.
Threats
- Clinical trial failures.
- Regulatory hurdles.
- Competition from larger pharmaceutical companies.
- Funding challenges.
Competitive Advantages
- Proprietary peptide-based drug development platform.
- Patent protection for drug candidates.
- Clinical trial data demonstrating safety and efficacy.
- Strategic collaborations with research institutions.
About IMMPF
Founded in 1999 and headquartered in London, ImmuPharma plc is a biopharmaceutical company dedicated to the discovery and development of peptide-based therapeutics. The company focuses on addressing unmet medical needs in autoimmunity, inflammation, and anti-infectives. Their lead product candidate, Lupuzor, is an autophagy immunomodulator currently in Phase III clinical trials for the treatment of lupus, a chronic autoimmune inflammatory disease affecting millions worldwide. Beyond Lupuzor, ImmuPharma is developing BioAMB, a peptide-based drug targeting Amphotericin-B formulations for fungal infections, and BioCin, a peptide-based antibacterial drug for high medical need cases. ImmuPharma collaborates with Centre National de la Recherche Scientifique for developing a peptide technology platform to treat diabetes, exploring glucagon-like peptide-1 agonists and glucagon antagonists. They also have a license and development agreement with Avion Pharmaceuticals LLC. ImmuPharma's strategy involves identifying and developing novel peptide-based therapies to improve patient outcomes in areas with significant unmet medical needs.
What They Do
- Discovers and develops peptide-based therapeutics.
- Focuses on therapies for autoimmunity and inflammation.
- Develops anti-infective drugs.
- Conducts clinical trials to evaluate drug candidates.
- Collaborates with research institutions and pharmaceutical companies.
- Seeks regulatory approvals for its products.
Business Model
- Develops and patents peptide-based drug candidates.
- Conducts preclinical and clinical trials to demonstrate safety and efficacy.
- Seeks regulatory approval from agencies like the FDA and EMA.
- Commercializes approved drugs directly or through partnerships.
Industry Context
ImmuPharma operates within the biotechnology industry, a sector characterized by high research and development costs, lengthy regulatory approval processes, and significant market potential for successful therapies. The autoimmune disease market, particularly for lupus treatments, is a growing area of focus. Competition includes companies developing novel biologics and small molecule drugs. ImmuPharma's peptide-based approach offers a differentiated strategy, but the company faces challenges from larger, more established players with greater resources. The biotechnology industry is driven by innovation, clinical trial outcomes, and regulatory approvals.
Key Customers
- Patients suffering from autoimmune diseases like lupus.
- Patients with fungal infections.
- Patients requiring antibacterial treatments.
- Healthcare providers prescribing ImmuPharma's drugs.
Financials
Chart & Info
ImmuPharma plc (IMMPF) stock price: Price data unavailable
Latest News
-
ImmuPharma raises up to £7.5m to accelerate diabetes drug development
proactiveinvestors.co.uk · Mar 17, 2026
Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for IMMPF.
Price Targets
Wall Street price target analysis for IMMPF.
MoonshotScore
What does this score mean?
The MoonshotScore rates IMMPF's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Timothy Paul McCarthy XIV, FCCA, MBA
CEO
Timothy Paul McCarthy XIV is a seasoned executive with FCCA and MBA credentials. His background includes extensive experience in financial management, corporate strategy, and leadership roles within various organizations. He has a proven track record of driving growth and improving operational efficiency. His expertise spans across multiple industries, providing him with a broad perspective on business challenges and opportunities.
Track Record: As CEO of ImmuPharma plc, Timothy Paul McCarthy XIV oversees the company's strategic direction and operational execution. He is responsible for guiding the development and commercialization of the company's pipeline products, including Lupuzor. Under his leadership, ImmuPharma has focused on advancing its clinical programs and securing partnerships to support its growth initiatives.
IMMPF OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that ImmuPharma plc may not meet the minimum financial standards or reporting requirements of higher tiers like OTCQX or OTCQB. Companies in this tier may have limited or no financial disclosure, which increases the risk for investors. Unlike companies listed on major exchanges like the NYSE or NASDAQ, OTC Other companies face fewer regulatory requirements and oversight, resulting in less transparency and potentially higher volatility.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited financial disclosure due to OTC Other tier status.
- Low trading volume and liquidity.
- Potential for price manipulation.
- Higher volatility compared to stocks listed on major exchanges.
- Increased risk of fraud or mismanagement.
- Verify the company's financial statements and SEC filings (if any).
- Research the background and experience of the management team.
- Assess the company's business model and competitive landscape.
- Evaluate the company's pipeline and clinical trial data.
- Check for any legal or regulatory issues.
- Monitor trading volume and price fluctuations.
- Consult with a financial advisor.
- Phase III clinical trial for Lupuzor suggests a degree of scientific validation.
- Collaboration with Centre National de la Recherche Scientifique indicates research credibility.
- Development of peptide-based therapeutics addresses unmet medical needs.
- Presence of a CEO with FCCA and MBA credentials.
- Founded in 1999, indicating some operational history.
ImmuPharma plc Stock: Key Questions Answered
What does ImmuPharma plc do?
ImmuPharma plc is a biopharmaceutical company focused on discovering and developing peptide-based therapeutics for autoimmune, inflammatory, and anti-infective diseases. Their lead product candidate, Lupuzor, is currently in Phase III clinical trials for the treatment of lupus, a chronic autoimmune inflammatory disease. The company also develops BioAMB for fungal infections and BioCin as an antibacterial drug. ImmuPharma collaborates with research institutions like Centre National de la Recherche Scientifique to expand its pipeline and address unmet medical needs.
What do analysts say about IMMPF stock?
AI analysis is currently pending for IMMPF. Given its OTC listing and development-stage pipeline, analyst coverage may be limited. Key valuation metrics will depend on the progress and potential success of Lupuzor and other pipeline candidates. Investors should closely monitor clinical trial results, regulatory milestones, and financial performance to assess the company's growth prospects. Due to the speculative nature of biotechnology stocks, a comprehensive risk assessment is crucial.
What are the main risks for IMMPF?
The main risks for ImmuPharma plc include the potential failure of clinical trials, particularly for Lupuzor, which is in Phase III. Regulatory hurdles and competition from larger pharmaceutical companies also pose significant challenges. Funding for ongoing research and development is a constant concern, especially given the company's OTC market listing and limited financial resources. The low liquidity and potential for price manipulation associated with OTC stocks further increase the investment risk.
What are the key factors to evaluate for IMMPF?
ImmuPharma plc (IMMPF) currently holds an AI score of 44/100, indicating low score. Key strength: Proprietary peptide-based drug development platform.. Primary risk to monitor: Potential: Failure of Lupuzor Phase III clinical trial.. This is not financial advice.
How frequently does IMMPF data refresh on this page?
IMMPF prices update in real time during U.S. market hours (9:30 AM-4:00 PM ET, weekdays). Fundamentals refresh after quarterly or annual filings. Analyst ratings and AI insights update daily. News is aggregated continuously from financial sources.
What has driven IMMPF's recent stock price performance?
Recent price movement in ImmuPharma plc (IMMPF) can be influenced by earnings results, analyst revisions, sector rotation, and broader market sentiment. Notable catalyst: Proprietary peptide-based drug development platform.. Check the News and Technical Analysis tabs for the latest drivers. Past performance does not predict future results.
Should investors consider IMMPF overvalued or undervalued right now?
Determining whether ImmuPharma plc (IMMPF) is overvalued or undervalued requires examining multiple metrics. Compare valuation ratios (P/E, P/S, EV/EBITDA) against sector peers for a comprehensive view.
What research should beginners do before buying IMMPF?
Before investing in ImmuPharma plc (IMMPF), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on available data and may be subject to change.
- AI analysis is pending and may provide further insights.